NK Cell‐Based Cancer Immunotherapies: Current Progress, Challenges and Emerging Opportunities
Journal of Biochemical and Molecular Toxicology · 2024-11 · 38 (11)
DOI: 10.1002/jbt.70044 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 06.11.2024. Verfasst von Mohammad Y Alshahrani und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Sciences, College of Applied Medical Science, King Khalid University, Abha, Saudi Arabia. Hauptthemen laut MEDLINE: Killer Cells, Natural, Neoplasms, Immunotherapy, Exosomes. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 128 Literaturangaben. Gefördert von: This study was supported by Large Research Group Project (Grant no. R.G.P.2/369/44)..
Abstract (Originalsprache)
Natural killer (NK) cells are vital innate immune cells that play a crucial role in cancer therapy. They are targeted by therapies designed to modulate, retain, and enhance their antitumor function in vivo. In addition to whole‐cell therapy, NK cell‐derived exosomes (NDEs) offer high immune safety and are easily subject to chemical, biological, and immunological modifications. This makes them suitable for use in combination with various current cancer therapies to enhance efficacy, treatment outcomes, and reduce side effects in vivo. This review aims to outline summarizes the antitumor potential of NK cells, as well as the current challenges and opportunities in NK cell‐based immunotherapies such as allogeneic and autologous NK cell transplantation, CAR NK cell therapy, and the use of cytokines and monoclonal antibodies. The review also explores the dual regulatory effects of tumor exosomes on NK cells, and highlights the potential of NDEs, either alone or in combination with other antitumor therapies, to reprogram the immunosuppressive tumor microenvironment and expedite the therapeutic effects of cancer immunotherapy in future clinical research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Laboratory Sciences, College of Applied Medical Science, King Khalid University, Abha, Saudi Arabia.
- Pharmacy Department, Faculty of Pharmacy, Tishk International University, Erbil, Kurdistan Region, Iraq.
- Department of Nuclear and Renewable Energy, Ural Federal University Named after the First President of Russia Boris Yeltsin, Ekaterinburg, Russia.
- Department of Technical Sciences, Western Caspian University, Baku, Azerbaijan.
- Department of Mechanical Engineering, Karpagam Academy of Higher Education, Coimbatore, India.
- Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Delta State University, Abraka, Delta State, Nigeria.
Förderung
- This study was supported by Large Research Group Project (Grant no. R.G.P.2/369/44).
Zitieren
APA
Alshahrani, M. Y., Uthirapathy, S., Kumar, A., Oghenemaro, E. F., R, R., Lal, M., Arora, I., Chauhan, A. S., Saud, M. J., & Hulail, H. M. (2024). NK Cell‐Based Cancer Immunotherapies: Current Progress, Challenges and Emerging Opportunities. Journal of Biochemical and Molecular Toxicology, 38(11). https://doi.org/10.1002/jbt.70044
Vancouver
Alshahrani MY, Uthirapathy S, Kumar A, Oghenemaro EF, R R, Lal M, et al. NK Cell‐Based Cancer Immunotherapies: Current Progress, Challenges and Emerging Opportunities. Journal of Biochemical and Molecular Toxicology. 2024;38(11). doi:10.1002/jbt.70044
BibTeX
@article{Alshahrani2024,
author = {Alshahrani, Mohammad Y and Uthirapathy, Subasini and Kumar, Abhinav and Oghenemaro, Enwa Felix and R, Roopashree and Lal, Madan and Arora, Isha and Chauhan, Ashish Singh and Saud, Mahmood Jumaa and Hulail, Hanen Mahmod},
title = {NK Cell‐Based Cancer Immunotherapies: Current Progress, Challenges and Emerging Opportunities},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2024},
volume = {38},
number = {11},
doi = {10.1002/jbt.70044}
}
EUVIMED